Managing Highly Insulin-Resistant Diabetes Mellitus: Weight Loss Approaches and Medical Management

被引:8
作者
Brown, Aparna [1 ]
Desai, Megha [1 ]
Taneja, Deepa [1 ]
Tannock, Lisa R. [1 ,2 ]
机构
[1] Univ Kentucky, Div Endocrinol & Mol Med, Lexington, KY 40536 USA
[2] Dept Vet Affairs, Lexington, KY USA
关键词
insulin resistance; weight loss; insulin sensitizers; U-500; insulin; CARDIOVASCULAR RISK REDUCTION; ISLET-AMYLOID POLYPEPTIDE; PREPARED MEAL PLAN; BODY-COMPOSITION; DISEASE RISK; DOUBLE-BLIND; LIFE-STYLE; OBESE; THERAPY; METFORMIN;
D O I
10.3810/pgm.2010.01.2110
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The prevalence of obesity and diabetes is epidemic. Severe insulin resistance (defined I as the need for >= 200 units of insulin per clay to achieve glycemic control) is commonly see 1 with obesity and can complicate diabetes management. The management of patients with diabetes who have severe insulin resistance is difficult. and at times frustrating and requires a multifaceted approach. Weight loss is the best treatment option, which can be a challenging task for patients to achieve and maintain. Medications that decrease insulin needs like metformin., thiazolidinediones, or pramlintide may, help, but some patients also need high Closes of insulin. This article reviews these different treatment options and provides practical advice on weight loss, use Of insulin sensitizers, and use of U-500 insulin.
引用
收藏
页码:163 / 171
页数:9
相关论文
共 68 条
[1]   Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis [J].
Amori, Renee E. ;
Lau, Joseph ;
Pittas, Anastassios G. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (02) :194-206
[2]   Weight loss and long-term follow-up of severely obese individuals treated with an intense behavioral program [J].
Anderson J.W. ;
Grant L. ;
Gotthelf L. ;
Stifler L.T.P. .
International Journal of Obesity, 2007, 31 (3) :488-493
[3]   Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: A 16 week, double-blind, placebo-controlled trial [J].
Anderson, James W. ;
Schwartz, Susan M. ;
Hauptman, Jonathan ;
Boldrin, Mark ;
Rossi, Maureen ;
Bansal, Vidhu ;
Hale, Cecilia A. .
ANNALS OF PHARMACOTHERAPY, 2006, 40 (10) :1717-1723
[4]   Obesity and disease management: Effects of weight loss on comorbid conditions [J].
Anderson, JW ;
Konz, EC .
OBESITY RESEARCH, 2001, 9 :326S-334S
[5]   Long-term weight maintenance after an intensive weight-loss program [J].
Anderson, JW ;
Vichitbandra, S ;
Qian, W ;
Kryscio, RJ .
JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, 1999, 18 (06) :620-627
[6]  
[Anonymous], 1998, OBES RES S, V2, p51s
[7]   METFORMIN - AN UPDATE [J].
BAILEY, CJ .
GENERAL PHARMACOLOGY, 1993, 24 (06) :1299-1309
[8]   Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones [J].
Bailey, CJ .
DIABETES OBESITY & METABOLISM, 2005, 7 (06) :675-691
[9]   BIGUANIDES AND NIDDM [J].
BAILEY, CJ .
DIABETES CARE, 1992, 15 (06) :755-772
[10]   Clinical experience with U-500 regular insulin in obese, markedly insulin-resistant type 2 diabetic patients [J].
Ballani, Piya ;
Tran, Michael T. ;
Navar, Maria D. ;
Davidson, Mayer B. .
DIABETES CARE, 2006, 29 (11) :2504-2505